Grifols Slows Alzheimer’s Progression With Plasmapheresis
Plasmapheresis with Grifols’ Albutein could provide a new treatment avenue for Alzheimer’s disease, but more data will be needed to convince.
You may also be interested in...
A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.
The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.